Vemurafenib, dabrafenib, and encorafenib, first-generation RAF inhibitors, were developed and utilized as monotherapies or in conjunction with MEK inhibitors to treat cancers harboring the BRAF (V600E) mutation [73]. This evidence concerns the gene MAP2K7 and cancer.